Diagnostic method for detecting an autoimmune disease
The present invention relates to a polypeptide or protein for use in a method of diagnosis or treatment of an autoimmune disease in a subject, characterized in that said polypeptide or protein comprises one or more epitopes derived from the protein DPPX. Further, the invention relates to a nucleic acid or vector encoding such polypeptide, to a cell comprising such a vector, to an in vitro diagnostic method and test kit involving such polypeptide, to a pharmaceutical composition comprising such polypeptide, to a medical device coated with such polypeptide or pharmaceutical composition and to methods for treating an autoimmune disease in a subject.
1. A method for determining the presence or absence of an autoantibody in a sample obtained from a subject, wherein the autoantibody is capable of binding to a protein dipeptidyl-peptidase-like protein-6 (DPPX), comprising:
a. contacting the sample with the protein DPPX, and
b. determining the presence or absence of the autoantibody in the sample,
wherein the protein DPPX comprises:
(i) the sequence according to SEQ ID NO: 1, 2, 3, or 4,
(ii) a polypeptide having the extracellular domain according to SEQ ID NO: 2 and the intracellular and transmembrane domains according to SEQ ID NO: 3 or 4,
(iii) a sequence with at least 90% sequence identity to SEQ ID NO: 1, 2, 3, or 4, or
(iv) a sequence with at least 90% sequence identity to the polypeptide having the extracellular domain according to SEQ ID NO: 2 and intracellular and transmembrane domains according to SEQ ID NO: 3 or 4.
2. The method of claim 1 , wherein the protein DPPX comprises the sequence according to SEQ ID NO: 1 or the sequence with at least 90% sequence identity to SEQ ID NO:1.
3. The method of claim 1 , wherein the protein DPPX comprises the sequence according to SEQ ID NO: 2 or the sequence with at least 90% sequence identity to SEQ ID NO. 2.
4. The method of claim 1 , wherein the protein DPPX comprises the sequence according to SEQ ID NO: 3 or the sequence with at least 90% sequence identity to SEQ ID NO: 3.
5. The method of claim 1 , wherein the protein DPPX comprises the sequence according to SEQ ID NO: 4 or the sequence with at least 90% sequence identity to SEQ ID NO:4.
6. The method of claim 1 , wherein the protein DPPX comprises the polypeptide having the extracellular domain according to SEQ ID NO: 2 and the intracellular and transmembrane domains according to SEQ ID NO: 3 or 4, or the sequence with at least 90% sequence identity to the polypeptide having the extracellular domain according to SEQ ID NO: 2 and intracellular and transmembrane domains according to SEQ ID NO: 3 or 4.
7. The method of claim 1 , wherein the protein DPPX comprises further amino acids at its N-terminus or C-terminus to facilitate purification of the protein.
8. The method of claim 1 , wherein the protein DPPX is linked to a reporter-molecule or a solid phase.
9. The method according to claim 1 , wherein the binding of the autoantibody from the sample to the protein DPPX is detected with an immunofluorescence-test, protein microarray, ELISA, luminiscence-test, blot, radioimmune test, western blot or dot blot.
10. The method of claim 1 , wherein the sample is from a subject having or suspected to have an autoimmune disease.
11. The method of claim 1 , wherein the protein DPPX is coated on a medical device.
12. The method of claim 1 , wherein the sample is a serum sample or a cerebrospinal fluid (CSF) sample.
13. The method of claim 1 , wherein the protein DPPX comprises SEQ ID NO:1.